(Q42519048)

1 November 2017

title

p63 expression in ovarian tumours: a marker for Brenner tumours but not transitional cell carcinomas (English)

1 reference

1 November 2017

Liao XY

1

1 reference

1 November 2017

Xue WC

2

1 reference

1 November 2017

Shen DH

3

1 reference

1 November 2017

Ngan HY

4

1 reference

1 November 2017

Siu MK

5

1 reference

1 November 2017

Cheung AN

6

1 reference

1 November 2017

publication date

1 October 2007

1 reference

1 November 2017

1 reference

1 November 2017

volume

51

1 reference

1 November 2017

issue

4

1 reference

1 November 2017

page(s)

477-483

1 reference

p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities

1 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2007.02804.X

p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2007.02804.X

Transitional cell carcinoma of the ovary: a morphologic study of 100 cases with emphasis on differential diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2007.02804.X

c-mos immunoreactivity aids in the diagnosis of gestational trophoblastic lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2007.02804.X

P63 expression in lung carcinoma: a tissue microarray study of 408 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2007.02804.X

Immunohistochemical analysis of uroplakins, urothelial specific proteins, in ovarian Brenner tumors, normal tissues, and benign and neoplastic lesions of the female genital tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2007.02804.X

Loss of p63 expression is associated with tumor progression in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2007.02804.X

p63 is a prostate basal cell marker and is required for prostate development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2007.02804.X

Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2007.02804.X

Immunohistochemical stains for p63 and alpha-methylacyl-CoA racemase, versus a cocktail comprising both, in the diagnosis of prostatic carcinoma: a comparison of the immunohistochemical staining of 430 foci in radical prostatectomy and needle biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2007.02804.X

Differential expression of p63 isoforms in normal tissues and neoplastic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2007.02804.X

p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2007.02804.X

Taking advantage of basic research: p63 is a reliable myoepithelial and stem cell marker

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2007.02804.X

P63 is expressed in basal and myoepithelial cells of human normal and tumor salivary gland tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2007.02804.X

Cloning and functional analysis of human p51, which structurally and functionally resembles p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2007.02804.X

Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2007.02804.X

10.1111/J.1365-2559.2007.02804.X

21 January 2018

Identifiers

DOI

1 reference

1 November 2017

1 reference